
Synthesis and biological evaluation of novel triazole derivatives as antifungal agents
-
关键词:
- Triazole
- / Antifungal
- / Structure-activity relationship
- / CYP51
English
Synthesis and biological evaluation of novel triazole derivatives as antifungal agents
-
Key words:
- Triazole
- / Antifungal
- / Structure-activity relationship
- / CYP51
-
-
-
[1] B.J. Kullberg, A.M. Oude Lashof, Epidemiology of opportunistic invasive mycoses, Eur. J. Med. Res. 7 (2002) 183-191.[1] B.J. Kullberg, A.M. Oude Lashof, Epidemiology of opportunistic invasive mycoses, Eur. J. Med. Res. 7 (2002) 183-191.
-
[2] D.A. Enoch, H.A. Ludlam, N.M. Brown, Invasive fungal infections: a review of epidemiology and management options, J. Med. Microbiol. 55 (2006) 809-818.[2] D.A. Enoch, H.A. Ludlam, N.M. Brown, Invasive fungal infections: a review of epidemiology and management options, J. Med. Microbiol. 55 (2006) 809-818.
-
[3] E. Rodriguez-Fernandez, J.L. Manzano, J.J. Benito, et al., Thiourea, triazole and thiadiazine compounds and their metal complexes as antifungal agents, J. Inorg. Biochem. 99 (2005) 1558-1572.[3] E. Rodriguez-Fernandez, J.L. Manzano, J.J. Benito, et al., Thiourea, triazole and thiadiazine compounds and their metal complexes as antifungal agents, J. Inorg. Biochem. 99 (2005) 1558-1572.
-
[4] H. Hof, Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine? Drug Resist. Updat. 11 (2008) 25-31.[4] H. Hof, Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine? Drug Resist. Updat. 11 (2008) 25-31.
-
[5] P. Eggimann, J. Garbino, D. Pittet, Management of Candida species infections in critically ill patients, Lancet Infect. Dis. 3 (2003) 772-785.[5] P. Eggimann, J. Garbino, D. Pittet, Management of Candida species infections in critically ill patients, Lancet Infect. Dis. 3 (2003) 772-785.
-
[6] J. Peman, E. Canton, A. Espinel-Ingroff, Antifungal drug resistance mechanisms, Expert. Rev. Anti. Infect. Ther. 7 (2009) 453-460.[6] J. Peman, E. Canton, A. Espinel-Ingroff, Antifungal drug resistance mechanisms, Expert. Rev. Anti. Infect. Ther. 7 (2009) 453-460.
-
[7] A.K. Gupta, E. Tomas, New antifungal agents, Dermatol. Clin. 21 (2003) 565-576.[7] A.K. Gupta, E. Tomas, New antifungal agents, Dermatol. Clin. 21 (2003) 565-576.
-
[8] G.R. Thompson Ⅲ, J. Cadena, T.F. Patterson, Overview of antifungal agents, Clin. Chest Med. 30 (2009) 203-215.[8] G.R. Thompson Ⅲ, J. Cadena, T.F. Patterson, Overview of antifungal agents, Clin. Chest Med. 30 (2009) 203-215.
-
[9] H. Ji, W. Zhang, Y. Zhou, et al., A three-dimensional model of lanosterol 14alphademethylase of Candida albicans and its interaction with azole antifungals, J. Med. Chem. 43 (2000) 2493-2505.[9] H. Ji, W. Zhang, Y. Zhou, et al., A three-dimensional model of lanosterol 14alphademethylase of Candida albicans and its interaction with azole antifungals, J. Med. Chem. 43 (2000) 2493-2505.
-
[10] Z. Guan, X. Chai, S. Yu, et al., Synthesis, molecular docking, and biological evaluation of novel triazole derivatives as antifungal agents, Chem. Biol. Drug. Des. 76 (2010) 496-504.[10] Z. Guan, X. Chai, S. Yu, et al., Synthesis, molecular docking, and biological evaluation of novel triazole derivatives as antifungal agents, Chem. Biol. Drug. Des. 76 (2010) 496-504.
-
[11] C. Sheng, W. Zhang, H. Ji, et al., Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking, J. Med. Chem. 49 (2006) 2512-2525.[11] C. Sheng, W. Zhang, H. Ji, et al., Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking, J. Med. Chem. 49 (2006) 2512-2525.
-
[12] National Committee for Clinical Laboratory Standards, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts Approved standard, Document M27-A2, National Committee for Clinical Laboratory Standards, Wayne, PA, 2002.[12] National Committee for Clinical Laboratory Standards, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts Approved standard, Document M27-A2, National Committee for Clinical Laboratory Standards, Wayne, PA, 2002.
-
[13] B. Yao, H. Ji, Y. Cao, et al., Synthesis and antifungal activities of novel 2-aminotetralin derivatives, J. Med. Chem. 50 (2007) 5293-5300.[13] B. Yao, H. Ji, Y. Cao, et al., Synthesis and antifungal activities of novel 2-aminotetralin derivatives, J. Med. Chem. 50 (2007) 5293-5300.
-
[14] X. Chai, J. Zhang, S. Yu, et al., Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols, Bioorg. Med. Chem. Lett. 19 (2009) 1811-1814.[14] X. Chai, J. Zhang, S. Yu, et al., Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols, Bioorg. Med. Chem. Lett. 19 (2009) 1811-1814.
-
[15] X. Chai, J. Zhang, H. Hu, et al., synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase, Eur. J. Med. Chem. 44 (2009) 1913-1920.[15] X. Chai, J. Zhang, H. Hu, et al., synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase, Eur. J. Med. Chem. 44 (2009) 1913-1920.
-
-

计量
- PDF下载量: 0
- 文章访问数: 1025
- HTML全文浏览量: 25